AI Summary
AMGN (AMGN) is currently trading at $381.04, up 2.99% in the last 24 hours. We maintain a HOLD rating pending clearer directional signals.
Price
Volume
P/E Ratio
Insider
Price Chart
Price Data
Fundamentals
Technical Analysis Summary
27 indicators analyzed
Technical picture is moderately bullish with 17 buy signals vs 5 sell signals. Trend favors long positions with proper risk management.
Technical Indicators
Momentum & trend signals
π‘ Technical indicators are tools, not guarantees. Always combine with fundamental analysis.
MACD
(12, 26, 9)Bollinger Bands
Volatility & breakout detection
Stochastic Oscillator
Momentum indicator (14,3,3)
π Neutral: AMGN stochastic is in the middle range (99.3). Wait for %K to enter overbought (80+) or oversold (20-) zones for clearer signals.
Average True Range (ATR)
π Volatility increasing - consider wider stops to avoid getting stopped out.
On-Balance Volume (OBV)
Volume-based momentum indicator
π Volume confirms uptrend: OBV rising above its average suggests institutional accumulation. Bullish signal for trend continuation.
Pivot Points
Key Support & Resistance Levels
All Pivot Levels
Price is trading above the pivot point at $369.23, indicating bullish bias. Watch R1 ($373.47) as the next target.
Fibonacci Retracement
| Level | Price | Type | Distance |
|---|---|---|---|
| 0% | $383.48 | Current | -0.1% |
| 23.6% | $354.68 | Support | +7.4% |
| 38.2% | $336.86 | Support | +12.1% |
| 50%β¦ | $322.46 | Support | +15.8% |
| 61.8%β¦ | $308.05 | Support | +19.6% |
| 78.6% | $287.55 | Support | +24.9% |
| 100% | $261.43 | Support | +31.8% |
VWAP (Volume Weighted Avg Price)
Parabolic SAR
Stop and Reverse Indicator
π Strong uptrend for 12 days. SAR at $342.38 acts as trailing stop. Ride the trend until SAR is hit.
Williams %R
π OVERBOUGHT: Williams %R at -0.7 indicates the stock is trading near its 14-day high. Strong momentum continues - may stay overbought in uptrends.
π CCI (Commodity Channel Index)
Momentum oscillator measuring price deviation
Strength: 50%
Previous CCI
+206.0
Typical Price
$378.48
SMA (20)
$342.12
Mean Deviation
$10.68
π₯ EXTREME OVERBOUGHT: CCI at 226.9 (above +200) - extraordinary bullish momentum! Strong uptrend continues, but pullback risk is elevated.
20-Day CCI History
π―Aroon Indicator(25-period)
π STRONG UPTREND: Aroon Up at 100 (above 70) with Aroon Down at 8 (below 30). Price made its 25-day high 0 day(s) ago. Trend is healthy - stay long and trail stops. Oscillator at 92.0 shows bullish bias.
π Rate of Change (ROC)Buy
Strong BullishUltimate Oscillator
Multi-timeframe momentum (7, 14, 28)
Keltner Channels
ATR-based volatility bands
Price just broke through the upper channel
π BULLISH BREAKOUT! Price 383.07 just broke above the upper Keltner Channel (369.41). This signals strong momentum. In uptrends, breakouts often continue. The EMA slope confirms bullish momentum - ride the trend.
TTM Squeeze
John Carter's Volatility Breakout
π NO SQUEEZE - BULLISH MOMENTUM: No squeeze currently (bands expanded). Momentum is positive and rising (21.45) - bullish continuation likely. Strong momentum - trend is healthy.
Elder Ray (Bull/Bear Power)
Dr. Alexander Elder's Power Index
π Strong bullish pressure - both bulls and bears above their normal ranges, bulls in control.
Force Index
Dr. Alexander Elder's Volume-Price Momentum
π Force Index shows bulls with slight edge. Short-term: 36.93M, Medium-term: 22.42M. Volume is normal.
Williams Alligator
Trend Direction & Strength
π Alligator is SATED - trend is losing momentum. Lines are converging. Previous bullish trend may be ending. Consider taking profits and wait for the next opportunity.
Donchian Channels
Richard Donchian's Breakout System (20-period)
Price broke above the 20-day high of $383.48
π BULLISH BREAKOUT! Price $383.07 broke above the 20-day high of $374.90. Strong breakout strength. Donchian breakouts often signal the start of new trends - consider long entries with stops below the middle band ($351.64).
Supertrend
ATR-Based Trend Following
π UPTREND active for 13 days. Price $383.07 is 21.7% above Supertrend $314.65. Strong trend strength. The Supertrend line serves as trailing support - consider taking partial profits.
Choppiness Index
Trend vs Range Detection (14-period)
π TRENDING MARKET (CHOP: 34.6). The market is in a clear trend with low choppiness. Choppiness is decreasing (3.2 points). Trading advice: Use TREND FOLLOWING strategies (moving average crossovers, breakouts, momentum). Avoid mean reversion or ranging strategies.
Valuation Metrics
Relative value indicators
π‘ PEG < 1 suggests undervalued relative to growth β’ EV/EBITDA accounts for debt
Historical Returns
Price performance across timeframes
π Insight: Strong recent momentum with positive year-to-date performance. Consider trailing stop to protect gains.
Seasonality Analysis
Market Comparison
Performance vs S&P 500
Dividend History
Past payments & growth
| Ex-Date | Amount |
|---|---|
| Nov 21, 2025Latest | $2.3800 |
| Aug 22, 2025 | $2.3800 |
| May 16, 2025 | $2.3800 |
| Feb 14, 2025 | $2.3800 |
| Nov 18, 2024 | $2.2500 |
| Aug 16, 2024 | $2.2500 |
| May 16, 2024 | $2.2500 |
| Feb 15, 2024 | $2.2500 |
Growth Metrics
Year-over-year performance
Growth rates calculated from trailing twelve months vs prior period
Analyst EPS Estimates
Consensus earnings projections
| Fiscal Year | Est. EPS | YoY Growth |
|---|---|---|
| FY26 | $21.96 | +68.8% |
| FY27 | $22.45 | +2.2% |
| FY28 | $22.83 | +1.7% |
Based on analyst consensus estimates. Actual results may vary.
Insider Activity
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Invalid Date | Unknown | SELL | 0 | $0K |
| Invalid Date | Unknown | SELL | 0 | $0K |
| Invalid Date | Unknown | SELL | 0 | $0K |
| Invalid Date | Unknown | SELL | 0 | $0K |
| Invalid Date | Unknown | SELL | 0 | $0K |
Recent News
CVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder
Anti-Obesity Drugs Market to Reach US$195.99 Billion by 2036 as GLP-1 Therapies Drive a Structural Shift in Weight Management
Amgen Hits 52-Week Highs: Buy Signal?
Oncology Biosimilars Research and Global Forecast Report 2025-2030: Targeted Therapies, Emerging Market Expansion, and Novel Biosimilar Formulations Drive Growth
CytomX Therapeutics to Present at Upcoming February Conferences
Targeted Cancer Therapy Market to Reach US$ 175.48 Billion by 2035 Driven by Precision Oncology Adoption, ADC Innovation, and Regulatory Productivity Says Astute Analytica
This Top Non-Tech AI Trade for 2026 Pays a Huge 11.6% Dividend
Kyowa Kirin erlangt Kontrolle ΓΌber Entwicklungs- und Kommerzialisierungsprogramm fΓΌr Rocatinlimab wieder, zeigt starkes Engagement im Bereich des ungedeckten medizinischen Bedarfs bei atopischer Dermatitis
Kyowa Kirin akan Mengambil Alih Semula Kawalan ke atas Rocatinlimab Development and Commercialization Program, Sekali Gus Menunjukkan Komitmen Kukuh bagi Menangani Keperluan Perubatan Tinggi yang Belum Dipenuhi dalam Dermatitis Atopik
Kyowa Kirin reprend le contrΓ΄le du programme de dΓ©veloppement et de commercialisation du rocatinlimab, manifestant ainsi son profond engagement visant Γ rΓ©pondre aux besoins mΓ©dicaux non satisfaits dans le domaine de la dermatite atopique
SEC Filings
πͺ Strengths
- βLimited positive signals in current data
π Opportunities
- βMarket conditions could present buying opportunities
β οΈ Weaknesses
- !No significant weaknesses identified
π Threats
- βBroader market volatility remains a risk
β‘ Catalysts
- β Earnings releases and guidance updates
β οΈ Key Risks
- !High debt-to-equity ratio increases financial risk
Are you an AI agent?
Help improve this research! Submit corrections, updates, or suggestions via Moltbook.
AI Agent Feedback
Are you an AI agent? Help improve this analysis!